Page 422 - medicina-integrativa_compress

CAPÍTULO 38 OSTEOPOROSIS 423

43. Heaney RP, Davies KM, Chen TC, et al: Human serum 64. Sato Y, Honda Y, Kaji M, et al: Amelioration of osteoporosis by
25-hydroxycholecalciferol response to extended oral dosing with menatetrenone in elderly female Parkinson’s disease patients with
cholecalciferol. Clin Nutr 77:204-210, 2003. vitamin D deficiency. Bone 31:114-118, 2002.
44. Laura AG, Hollis BW, Heaney RP: Vitamin D 2 is much less effective 65. Alexandersen P, Toussaint A, Christiansen C, et al: Ipriflavone in the
than D 3 in humans. J Clin Endocrin Metab 89:5387-5391, 2004. treatment of postmenopausal osteoporosis: A randomized controlled
45. Papadimitropoulos E, Wells G, Shea B, et al: Meta-analyses of trial. JAMA 285:1482-1488, 2001.
therapies for postmenopausal osteoporosis: VIII. Meta-analysis of the 66. Zofkova I, Bahbouh R, Hill M: The pathophysiologic implications of
efficacy of vitamin D treatment in preventing osteoporosis in circulating androgens on bone mineral density in a normal female
postmenopausal women. Endocr Rev 23:560-569, 2002. population. Steroids 65:857-861, 2000.
46. Bischoff-Ferrari HA, Willett WC, Wong JB, et al: Fracture prevention 67. Garnero P, Sornay-Rendu E, Claustrat B, Delmas PD: Biochemical
with vitamin D supplementation: A meta-analysis of randomized markers of bone turnover, endogenous hormones, and the risk of
controlled trials. JAMA 293:2257-2264, 2005. fractures in postmenopausal women: The OFELY study. J Bone
47. Venning G: Recent developments in vitamin D deficiency and muscle Miner Res 15:1526-1536, 2000.
weakness among elderly people. BMJ 330:524-526, 2005. 68. Dalsky G, Stocke KS, Ehsani AA, et al: Weight-bearing exercise
48. Sato Y, Iwamoto J, Kanoko T, Satoh K: Low-dose vitamin D prevents training and lumbar bone mineral content in postmenopausal
muscular atrophy and reduces falls and hip fractures in women after women. Ann Intern Med 108:824-828, 1988.
stroke: A randomized controlled trial. Cerbrovasc Dis 20:187-192, 2005. 69. Menkes A, Mazels S, Redmond RA, et al: Strength training increases
49. Dhesi JK, Jackson SH, Bearne LM, et al: Vitamin D supplementation regional bone mineral density and bone remodeling in middle-aged
improves neuromuscular function in older people who fall. Age and older men. J Appl Physiol 74:2478-2484, 1993.
Ageing 33:589-595, 2004. 70. Price R, Devine A, Dick I, et al: The effects of calcium
50. Bischoff-Ferrari HA, Dietrich T, Orav EJ, et al: Higher supplementation (milk powder or tablets) and exercise on bone
25-hydroxyvitamin D concentrations are associated with better density in postmenopausal women. J Bone Miner Res 10:1068-1075,
lower extremity function in both active and inactive persons aged 1995.
≥ 60 y. Am J Clin Nutr 80:752-758, 2004. 71. Cummings SR, Nevitt MC, Browner WS, et al: Risk factors for hip
51. Hall SI, Greendale GA: The relation of dietary vitamin C intake to fractures in white women. Study of Osteoporotic Fractures Research
bone mineral density: Results from the PEPI study. Calcif Tissue Int Group. N Engl J Med 332:767-773, 1995.
63:183-189, 1998. 72. Cummings SR, Karpf DB, Haris F, et al: Improvement in spine bone
52. Hodges SJ, Pilkington MJ, Stamp TC, et al: Depressed levels of density and reduction in risk of vertebral fractures during treatment
circulating menaquinones in patients with osteoporotic fractures of with anti-resorptive drugs. Am J Med 112:281-289, 2002.
the spine and femoral neck. Bone 12:387-389, 1991. 73. Rosen CJ: Postmenopausal osteoporosis. N Engl J Med 353:
53. Hodges SJ, Akesson K, Vergnaud P, et al: Circulating levels of 595-603, 2005.
vitamins K 1 and K 2 decreased in elderly women with hip fracture. 74. Cummings SR, Black DM, Thompson DE, et al: Effect of alendronate
J Bone Miner Res 8:1241-1245, 1993. on risk of fracture in women with low bone density but without
54. Feskanich D, Weber P, Willett WC, et al: Vitamin K intake and vertebral fractures: Results from the Fracture Intervention Trial.
hip fractures in women: A prospective study. Am J Clin Nutr 69: JAMA 280:2077-2082, 1998.
74-79, 1999. 75. Harris ST, Watts NB, Genant HK, et al: Effects of risedronate
55. Szulc P, Chapuy MC, Meunier PJ, Delmas PD: Serum treatment on vertebral and nonvertebral fractures in women with
undercarboxylated osteocalcin is a marker of the risk of hip fracture postmenopausal osteoporosis: A randomized controlled trial.
in older women. J Clin Invest 91:1769-1774, 1993. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.
56. Vergnaud P, Garnero P, Meunier PJ, et al: Undercarboxylated JAMA 282:1344-1352, 1999.
osteocalcin measured with specific immunoassay predicts hip fracture 76. Ettinger B, Black DM, Mitlack BH, et al, for Multiple Outcomes of
in elderly women: The EPIDOS study. J Clin Endocrinol Metab Raloxifene Evaluation (MORE) Investigators: Reduction of vertebral
82:717-718, 1997. fracture risk in postmenopausal women with osteoporosis treated
57. Szulc P, Chapuy MC, Meunier PJ, Delmas PD: Serum uncarboxylated with raloxifene: Results from a 3-year randomized clinical trial.
osteocalcin is a marker of the risk of hip fracture: A three-year follow- JAMA 282:637-645, 1999.
up study. Bone 18:487-488, 1996. 77. Downs RW Jr, Bell NH, Ettinger MP, et al: Comparison of alendronate
58. Sato Y, Honda Y, Kunoh H, Oizumi K: Long-term oral and intranasal calcitonin for treatment of osteoporosis in
anticoagulation reduces bone mass in patients with previous postmenopausal women. J Clin Endocrinol Metab 85:1783-1788, 2000.
hemispheric infarction and nonrheumatic atrial fibrillation. Stroke 78. Hochberg M: Preventing fractures in postmenopausal women with
28:2390-2394, 1997. osteoporosis: A review of recent controlled trials of antiresorptive
59. Shiraki M: [Vitamin K 2 ]. Nippon Rinsho 56:1525-1530, 1998. agents. Drugs Aging 17:317-330, 2000.
79. Cosman F, Nieves J, Zion M, et al: Daily and cyclic parathyroid
© Elsevier. Es una publicación MASSON. Fotocopiar sin autorización es un delito.
60. Braam LA, Knapen MH, Geusens P, et al: Vitamin K 1
supplementation retards bone loss in postmenopausal women hormone in women receiving alendronate. N Engl J Med 353:
between 50 and 60 years of age. Calcif Tissue Int 73:21-26, 2003. 566-75, 2005.
61. Ushiroyama T, Ikeda A, Ueki M: Effect of continuous combined 80. Black DM, Bilezikian JP Ensrud KE, et al: One year of alendronate
therapy with vitamin K 2 and Vitamin D 3 on bone mineral density and after one year of parathyroid hormone (1-84) for osteoporosis. N
coagulofibrinolysis function in postmenopausal women. Maturitas Engl J Med 353:555-565, 2005.
25:211-221, 2002. 81. Li F, Harmer P, Fisher KJ, et al: Tai Chi and fall reductions in older
adults: A randomized controlled trial. J Gerontol 60:187-194, 2005.
62. Iwamoto J, Takeda T, Ichimura S: Treatment with vitamin D 3
and/or vitamin K 2 for postmenopausal osteoporosis. Keio J Med 82. Qin L, Au S, Choy W, et al: Regular Tai Chi Chuan exercise may
52:147-150, 2003. retard bone loss in postmenopausal women: A case-control study.
63. Iwamoto J, Takeda T, Ichimura S: Effect of combined administration Arch Phys Med Rehabil 83:1355-1359, 2002.
of vitamin D 3 and vitamin K 2 on bone mineral density of the lumbar 83. Chan K, Qin L, Lau M, et al: A randomized, prospective study of the
spine in post-menopausal women with osteoporosis. effects of Tai Chi Chun exercise on bone mineral density in
J Orthoped Sci 5:546-551, 2000. postmenopausal women. Arch Phys Med Rehabil 85:717-722, 2004.